Please use this identifier to cite or link to this item:
Title: Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial.
Authors: Currow, David C;Ekstrӧm, Magnus;Louw, Sandra;Hill, Julie;Fazekas, Belinda;Clark, Katherine;Davidson, Patricia M;McDonald, Christine F;Sajkov, Dimitar;McCaffrey, Nikki;Doogue, Matthew;Abernethy, Amy P;Agar, Meera
Affiliation: McCloud Consulting Group, Narabang Way, Belrose, New South Wales, Australia
Deakin Health Economics, School of Health and Social Development, Deakin University, Victoria, Australia
Flinders Medical Centre, Department of Respiratory & Sleep Medicine, Medical Centre Drive, Bedford Park, South Australia, Australia
Austin Health, Heidelberg, Victoria, Australia
Discipline of Palliative and Supportive Services, Flinders University, South Australia, Australia
IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia
University of Sydney, Northern Clinical School, Royal North Shore Hospital, St Leonard's, New South Wales
Department of Clinical Sciences, Division of Respiratory Medicine & Allergology, Lund University, Lund, Sweden
School of Nursing, Johns Hopkins University, Baltimore, United States of America
Duke University, Carey, North Carolina, United States of America
University of Otago, Christchurch, New Zealand
Issue Date: 25-Oct-2018
EDate: 2018-10-25
Citation: The European respiratory journal 2018; online first: 25 October
Abstract: Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated?Two hundred and twenty three participants with chronic breathlessness (modified Medical Research Council (mMRC) breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25 mg-100 mg (titrated upwards over nine days) or placebo for four weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness >15% from baseline on a 100 mm visual analogue scale (VAS).The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26-28 (odds ratio [OR] 1·00, 95% CI 0.71-1·40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than placebo over the four weeks (OR 0·21, 95% CI 0·01-0·41, p=0·044). No differences in performance status, anxiety and depression, nor survival were observed. Adverse event rates were similar between arms.Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.
DOI: 10.1183/13993003.01270-2018
ORCID: 0000-0001-6481-3391
PubMed URL: 30361250
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.